- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT02770001
Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population
Investigating the Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population
Background: In genetic studies, the quality of DNA samples is tested first. Samples that are low-quality are not used. Some studies involve minority ethnic groups. And example is admixed African American. These studies often have small sample sizes. It is important to make sure samples are not discarded unnecessarily. This may happen by using quality control (QC) thresholds for homogenous groups. These may not be appropriate for an admixed group. Researchers want to study samples that failed certain QC tests. They want to see if this has to do with the ancestry of the outliers or the quality of the samples.
Objectives:
To study samples that fail heterozygosity and sample genotype call rate QC. To see if the failing rates have to do with the ancestry composition of the outliers or the quality of the samples.
Eligibility:
No new participants. Researchers will review data that has already been collected.
Design:
Researchers will study DNA samples in a lab.
The samples will not include data that can identify the person the sample came from.
Aperçu de l'étude
Statut
Les conditions
Description détaillée
The purpose of this IRB proposal is to gain access to genetic data generated from participants of publically-funded genomic studies and deposited into dbGaP. It is our intention to use dbGaP data to conduct secondary analysis of the influence of admixture on the outcome of data quality control (QC) in genetic association studies to inform future studies of the optimal QC metric for the genetic association analysis of admixed population. The data we intend to use is deposited in dbGaP and is from the Michigan University Health and Retirement Study (HRS). This protocol is being sent to you because of a dbGaP requirement for this specific de-identified dataset to be reviewed by an IRB as that was not in the protocol.
This work will require the use of statistical analyses tools to estimate the genetic ancestry make-up of each sample, from the genotype data, and determine how that ancestry relates to QC outcomes (i.e. whether or not the sample might be excluded from an analysis due to its ancestral genetic composition rather that the sample genetic quality).
Objectives and specific aims: This work aims to investigate samples failing heterozygosity and sample genotype call rate quality control (QC) to determine whether or not the samples call rate and heterozygosity rate have to do with the ancestry composition of the outliers rather than the quality of the samples and inform future studies of potential loss if general QC is applied to genetic data of admixed sample sets.
Rationale and Background: In genetic association studies DNA sample quality can vary largely across study participants and such variation has an impact on genotype call rate and genotype accuracy; samples of low DNA quality tend to have lower genotype call rate and genotype accuracy. Heterozygosity rate (proportion of heterozygous loci per individual) and genotype failure rate (proportion of missing genotypes per individual) are jointly and routinely used to identify samples with low DNA quality at the data quality control (QC) stage of genetic association studies. Excessive heterozygosity rate may indicate sample contamination whilst a reduced heterozygosity rate could indicate inbreeding [1]. Samples with 3-7% [2,3] genotype call-rate and heterozygosity > 2-3 standard deviations from the mean heterozygosity are usually excluded from genetic case-control studies.
Generally, the sample size of genetic association studies involving minority ethnic groups such as admixed African American tends to be small. It is hence important to ensure samples are not discarded unnecessarily, resulting into reduced statistical power, by using QC thresholds applied to homogenous groups which might not be appropriate for an admixed sample set. The aim of this analysis is to investigate samples failing heterozygosity and sample genotype call rate QC to determine whether or not the samples call rate and heterozygosity rate have to do with the ancestry composition of the outliers rather than the quality of the samples. The motivation is to inform future studies of potential loss if general
Type d'étude
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
- All the genotype data will be used and no individual will be excluded based on any phenotype.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Continental genetic ancestry fraction
Délai: Study Completion
|
Study Completion
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Heterozygosity rate
Délai: Study Completion
|
Study Completion
|
Collaborateurs et enquêteurs
Les enquêteurs
- Chercheur principal: Sharon K Davis, National Human Genome Research Institute (NHGRI)
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Réel)
Achèvement de l'étude (Réel)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
- 999916110
- 16-HG-N110
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur African American Genetics
-
University of UtahNational Cancer Institute (NCI)RecrutementFatigue | Mode de vie sédentaire | Carcinome métastatique de la prostate | Cancer de la prostate de stade IV AJCC (American Joint Committee on Cancer) v8 | Stade IVA Cancer de la prostate AJCC (American Joint Committee on Cancer) v8 | Stade IVB Cancer de la prostate AJCC (American Joint Committee...États-Unis
-
Jonsson Comprehensive Cancer CenterPas encore de recrutementCarcinome de la prostate | Stade IVB Cancer de la prostate American Joint Committee on Cancer (AJCC) v8États-Unis
-
Rashmi Verma, MDNational Cancer Institute (NCI)RecrutementCarcinome de la prostate résistant à la castration | Adénocarcinome métastatique de la prostate | Stade IVB Cancer de la prostate American Joint Committee on Cancer (AJCC) v8États-Unis
-
Jonsson Comprehensive Cancer CenterViewray Inc.Actif, ne recrute pasProgression de l'APS | Adénocarcinome de la prostate de stade III AJCC v7 | Adénocarcinome de la prostate de stade II AJCC v7 | Niveau PSA supérieur à 0,03 | Adénocarcinome de la prostate de stade I AJCC (American Joint Committee on Cancer) v7États-Unis
-
Emory UniversityNational Cancer Institute (NCI)RetiréCancer du sein pronostique de stade IV AJCC v8 | Tumeur maligne métastatique dans le cerveau | Carcinome du sein métastatique | Cancer du sein anatomique de stade IV American Joint Committee on Cancer (AJCC) v8
-
NRG OncologyNational Cancer Institute (NCI)Actif, ne recrute pasCancer du sein anatomique de stade IV AJCC v8 | Cancer du sein pronostique de stade IV AJCC v8 | Tumeur maligne métastatique dans l'os | Tumeur maligne métastatique dans les ganglions lymphatiques | Tumeur maligne métastatique dans le foie | Carcinome du sein métastatique | Tumeur maligne métastatique... et d'autres conditionsÉtats-Unis, Canada, Arabie Saoudite, Corée, République de
-
Jonsson Comprehensive Cancer CenterAstraZenecaRésiliéCarcinome épidermoïde oropharyngé | Carcinome oropharyngé de stade clinique III médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé de stade clinique II médié par le VPH (p16 positif) AJCC v8 | Carcinome oropharyngé pathologique de stade I médié par le VPH (p16 positif) AJCC... et d'autres conditionsÉtats-Unis
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); Highlight TherapeuticsActif, ne recrute pasLéiomyosarcome | Tumeur maligne de la gaine du nerf périphérique | Sarcome synovial | Sarcome pléomorphe indifférencié | Sarcome osseux pléomorphe indifférencié de haut grade | Myxofibrosarcome | Sarcome des tissus mous de stade II du tronc et des extrémités AJCC v8 | Sarcome des tissus mous de... et d'autres conditionsÉtats-Unis